Deutsch Bryant et al. reagieren auf unbegründete Kritik an ihrer Meta-Analyse durch Popp et al. und heben schwerwiegende Mängel einschließlich nicht unterstützter Behauptungen hervor. Lesen
Australian Phillip Altman BPharm (Hons), MSc, PhD gives his detailed comparison of ivermectin and Molnupiravir which Merck is developing as an oral treatment for covid.
A recent report on Ros Atkins’ show on BBC News Channel (16 September 2021) is analysed and found to be misleading, biased and obsessively featuring
Authors of Bryant et al. respond to unfounded criticisms of their meta analysis by Popp et al. and highlight serious flaws including unsupported assertions. Read
Transparency Statement: The team at Bird are transparent in our operations. Bird is a campaign managed through EbMCsquared, a not-for-profit Community Interest Company. It means 100% of profits after tax are reinvested into the business or to the advancement of our social purpose, for example to work on projects such as the Ivermectin campaign. We are here to promote and provide evidence for health and wellbeing, to inform decision-making on matters of public health and safety. We do this to advance health and wellbeing for the benefit of humankind.
Disclaimer: Nothing on this Website provides medical advice or any form of diagnosis or treatment of any kind to web users. Medical decisions should be made by the patient’s physician who can consider a review of the BIRD materials and knowledge of the patient’s medical history and condition. All information provided on the BIRD website or in connection with the Website are offered to promote consideration by trained health care professionals of possible treatments and for general informational purposes and are not medical advice to users. Errors and Omissions excepted.
Please support our campaign with a monthly or a single amount to help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.
Bird Group/EBMC Squared is a not-for-profit Community Interest Company (CIC).
All funds received will be invested in our activities to promote public health and wellbeing.
Your monthly or single contribution will help us keep pressure on authorities to approve the safe drug ivermectin that will help beat covid-19 and save lives around the world.
